GLP-1RA for glycaemic control and obesity as add on therapy for type 2 diabetes
Authors/Creators
- 1. National Diabetes Hospital and Department of Medicine, Faculty of Medicine, University of Tripoli, Tripoli, Libya
Description
Diabetes mellitus (DM) is a complex and chronic illness requiring continuous medical care. Type 2 diabetes (T2D) is commonly associated with obesity, hypertension, and a tendency to develop thrombosis, and increase risk of cardiovascular diseases (CVD). Diabesity is a term used to indicate an coexistence of obesity and DM. Diabesity increases as obesity is an emerging epidemic of modern societies, the co-incidence with DM is also rising, so a joint plan of anti-obesity and anti-hyperglycemia for the management approaches. Therefore, this study aimed to identify the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on bodyweight and glycemic response in obese Libyan patients with T2D at the National Diabetes Centre in Tripoli, between July 2013 and May 2022. This prospective study included obese adults with T2D who were newly prescribed GLP-1RA therapy for six months with dulaglutide once weekly or liraglutide once daily. The study included 170 diabetic patients were started on GLP1-RA as add on therapy to their treatment, with a regular follow up with dietitian and their physicians to adjusted their glucose lowering medications, than comparing the effect of these agents on bodyweight and the level of glycated hemoglobin before and after 24 weeks of treatment. Most of the patients (n = 99, 58.23%) were in the age period from 54 to 74 years old and 101 of whom were female subjects (59.4%), with a mean duration of DM equal to 8.8 ± 7.3 years. The patients were divided randomly into two groups, the first group included 110 patients who received liraglutide pens showed a significantly reduction in HbA1c from 9.6% (± 1.54) to 7.4% (± 1.03) by p < 0.001 and a significantly weight loss from 88.3 kg (± 10.68) to 80.8 kg (± 11.83) by p < 0.001. The reported adverse events were in 23 cases of minor hypoglycemia due to gastrointestinal upset. The other group included 60 patients for dulaglutide pens showed a significant decrease in HbA1c = 9.6% (± 1.54) to 7.1% (± 1.2) by p < 0.05 and a significant reduction of bodyweight from 88.3 kg (± 10.68) to 83.8 kg (± 16.3) by p < 0.05. The reported adverse events were mild transient gastrointestinal distressed for initial week of start than subside with regular intake. Whereas, 115 patients (67.6%) with HbA1c above 10.0% before start therapy, no patient with HbA1c above 10.0% after six months of both GLP-RA agents therapy. Thus, uses of GLP-RA as add on therapy for obese patients with T2D significantly improved the glycaemic control with less hypoglycaemia, accordingly, reduce insulin requirement for the blood glucose control and loss in bodyweight. It can thus be concluded that GLP-1RA therapy is an effective treatment option when used in the obese patients with DM.